trending Market Intelligence /marketintelligence/en/news-insights/trending/yLW20EgU0YlJqo5wHwkEGg2 content esgSubNav
In This List

Come True Biomedical Q1 loss narrows YOY

Case Study

A Green Lender Adopts a Robust Approach for Assessing Project Finance Credit Risks

Case Study

An Asset Manager Meets Client Redistribution Demands for Excel-based Statements

Podcast

MediaTalk | Season 2
Ep.1: Broadcast's Big Year

Blog

Global M&A by the Numbers Q4 2023


Come True Biomedical Q1 loss narrows YOY

Come True Biomedical Inc. said its first-quarter normalized net income came to a loss of 17 Taiwan cents per share, compared with a loss of 23 cents per share in the year-earlier period.

Normalized net income, which excludes unusual gains or losses on a pre- and after-tax basis, was a loss of NT$5.2 million, compared with a loss of NT$7.3 million in the prior-year period.

The normalized profit margin increased to negative 12.5% from negative 20.1% in the year-earlier period.

Total revenue rose 14.9% on an annual basis to NT$41.9 million from NT$36.5 million, and total operating expenses came to NT$51.9 million, compared with NT$52.0 million in the prior-year period.

Reported net income totaled a loss of NT$7.4 million, or a loss of 23 cents per share, compared to a loss of NT$9.6 million, or a loss of 30 cents per share, in the prior-year period.

As of May 12, US$1 was equivalent to NT$32.56.